Page last updated: 2024-10-30

lansoprazole and Ulcer

lansoprazole has been researched along with Ulcer in 13 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.

Research Excerpts

ExcerptRelevanceReference
"There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD."9.41Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023)
"To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer."8.31Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023)
"The objective of this study was to formulate and evaluate the lansoprazole (LPZ)-loaded microparticles to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease (GERD)."7.79A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation. ( Alai, M; Lin, WJ, 2013)
"The effect of lansoprazole, a proton pump inhibitor (PPI), on indomethacin-induced small intestinal ulceration was examined in rats, particularly in relation to heme oxygenase (HO)-1."7.76Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1. ( Amagase, K; Higuchi, K; Kakimoto, K; Kato, S; Murano, M; Nishio, H; Takeuchi, K; Tokioka, S; Umegaki, E; Yoda, Y, 2010)
"There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD."5.41Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023)
"A combination package containing delayed-release capsules of the proton pump inhibitor lansoprazole (15 mg once daily) and tablets of the NSAID naproxen (375 or 500 mg twice daily) has been approved for reducing the risk of NSAID-associated gastric ulcers in NSAID-requiring patients with a documented history of gastric ulcer."4.82Delayed-release lansoprazole plus naproxen. ( Curran, MP; Wellington, K, 2004)
"To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer."4.31Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023)
"The objective of this study was to formulate and evaluate the lansoprazole (LPZ)-loaded microparticles to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease (GERD)."3.79A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation. ( Alai, M; Lin, WJ, 2013)
"The effect of lansoprazole, a proton pump inhibitor (PPI), on indomethacin-induced small intestinal ulceration was examined in rats, particularly in relation to heme oxygenase (HO)-1."3.76Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1. ( Amagase, K; Higuchi, K; Kakimoto, K; Kato, S; Murano, M; Nishio, H; Takeuchi, K; Tokioka, S; Umegaki, E; Yoda, Y, 2010)
"Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0."2.68Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997)
"Lansoprazole 30 mg was started."1.33Pill esophagitis caused by telithromycin: a case report. ( Büyükberber, M; Demirci, F; Gülşen, MT; Kis, C; Koruk, M; Savaş, MC, 2006)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (15.38)18.2507
2000's6 (46.15)29.6817
2010's3 (23.08)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Miao, T1
Zhang, Y1
Bai, L1
Yang, X1
Wen, X1
Gao, N2
Yan, S2
Chen, B2
Kitagawa, T1
Sato, K1
Yokouchi, Y1
Tominaga, K1
Ito, S1
Maetani, I1
Yoda, Y1
Amagase, K1
Kato, S1
Tokioka, S1
Murano, M1
Kakimoto, K1
Nishio, H1
Umegaki, E1
Takeuchi, K1
Higuchi, K1
Alai, M1
Lin, WJ1
Guda, N1
Vakil, N1
Sawhney, MS1
Nelson, DB1
Curran, MP1
Wellington, K1
Büyükberber, M1
Demirci, F1
Savaş, MC1
Kis, C1
Gülşen, MT1
Koruk, M1
Sontag, SJ1
Kogut, DG1
Fleischmann, R1
Campbell, DR1
Richter, J1
Robinson, M1
McFarland, M1
Sabesin, S1
Lehman, GA1
Castell, D1
Kobayashi, S1
Kawabe, N1
Miyata, F1
Ito, H1
Kazumiya, H1
Murase, K1
Kurokawa, S1
Fujishima, K1
Stolte, M1
Vieth, M1
Schmitz, JM1
Alexandridis, T1
Seifert, E1
Byrne, M1
Sheehan, K1
Kay, E1
Patchett, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976]Phase 458 participants (Actual)Interventional2006-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hamilton Depression Rating Scale (HAM-D-24)

The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4

,
Interventionunits on a scale (Mean)
prenaprosyn Baselinepostnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone6.456.384.544.142.62
Placebo7.106.575.535.076.21

Insomnia Severity Index (ISI)

The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
Prenaprosyn BaselinePostnaprosyn baselineWeek 1Week 2Week 4
Eszopiclone18.8518.0011.2810.618.38
Placebo20.2616.7812.8512.7413.75

Mean Sleep Onset Latency (SOL)

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionminutes (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone38.2822.3617.5015.28
Placebo34.1127.0023.1019.91

Mean Subjective Sleep Diary Derived Total Sleep Time (TST)

Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4

,
InterventionMinutes (Mean)
postnaprosyn baselineweek 1week 2Week 4
Eszopiclone316.96403.47421.97411.97
Placebo380.45375.56382.11388.96

Number of Awakenings

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionawakenings (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone2.291.311.351.33
Placebo2.081.982.132.34

Patient Global Impression of Pain Ratings

Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone4.023.543.303.08
Placebo3.903.824.013.80

Roland Morris Low Back Pain Inventory (RMLBPI)

"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4

,
Interventionunits on a scale (Mean)
prenaprosyn Baselinepostnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone12.279.979.107.636.59
Placebo11.3310.309.059.327.94

Sleep Quality Ratings

Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone4.525.996.186.38
Placebo4.444.905.335.29

Visual Analog Scale Pain Ratings (VAS)

Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4

,
Interventionunits on a scale (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone48.5140.7234.7031.69
Placebo53.7951.9951.2551.60

Wake Time After Sleep Onset

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionminutes (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone91.5149.3437.0736.74
Placebo81.4376.7181.3276.18

Reviews

2 reviews available for lansoprazole and Ulcer

ArticleYear
Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis.
    Revista espanola de enfermedades digestivas, 2023, Volume: 115, Issue:4

    Topics: Endoscopic Mucosal Resection; Humans; Lansoprazole; Proton Pump Inhibitors; Stomach Neoplasms; Stoma

2023
Delayed-release lansoprazole plus naproxen.
    Drugs, 2004, Volume: 64, Issue:17

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2004

Trials

2 trials available for lansoprazole and Ulcer

ArticleYear
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    The American journal of gastroenterology, 1997, Volume: 92, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Meth

1997
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
    Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method;

2000

Other Studies

9 other studies available for lansoprazole and Ulcer

ArticleYear
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
    Alternative therapies in health and medicine, 2023, Volume: 29, Issue:2

    Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga

2023
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
    Alternative therapies in health and medicine, 2023, Volume: 29, Issue:2

    Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga

2023
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
    Alternative therapies in health and medicine, 2023, Volume: 29, Issue:2

    Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga

2023
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
    Alternative therapies in health and medicine, 2023, Volume: 29, Issue:2

    Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga

2023
A case of lansoprazole-associated collagenous colitis with longitudinal ulcer.
    Journal of gastrointestinal and liver diseases : JGLD, 2013, Volume: 22, Issue:1

    Topics: Aged; Anti-Ulcer Agents; Biopsy; Colitis, Collagenous; Colitis, Ischemic; Colon; Colonic Diseases; C

2013
Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2010, Volume: 61, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colony Co

2010
A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation.
    Journal of microencapsulation, 2013, Volume: 30, Issue:6

    Topics: Acids; Acrylic Resins; Animals; Anti-Ulcer Agents; Delayed-Action Preparations; Gastroesophageal Ref

2013
Low-dose aspirin: protection from the panacea.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2002
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
    Gastroenterology, 2003, Volume: 124, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru

2003
Pill esophagitis caused by telithromycin: a case report.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2006, Volume: 17, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Endoscopy,

2006
[A case of Behcet's syndrome associated with esophageal ulcer].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1998, Dec-10, Volume: 87, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents; Anti-Ulcer Agents; Behcet

1998
Symptomatic ulceration of an acid-producing oesophageal inlet patch colonized by helicobacter pylori.
    Endoscopy, 2002, Volume: 34, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Endoscopes; Esophagus; Helicobact

2002